Breast cancer

  • Currently 0.00/5

Rating: 0.0/5 (0 votes cast) login to rate

Add to Favorite Print This Page Publish on Twitter
Bookmark and Share
Breast cancer
Classification and external resources

Mammograms showing a normal breast (left) and a breast cancer (right).
ICD-10 C50.
ICD-9 174-175,V10.3
OMIM 114480
DiseasesDB 1598
MedlinePlus 000913
eMedicine med/2808 med/3287 radio/115 plastic/521
MeSH D001943
GeneReviews 2=

Breast cancer (malignant breast neoplasm) is cancers originating from breast tissue, most commonly from the inner lining of milk ducts or the lobules that supply the ducts with milk. Cancers originating from ducts are known as ductal carcinomas; those originating from lobules are known as lobular carcinomas. There are many different types of breast cancer, with different stages (spread), aggressiveness, and genetic makeup; survival varies greatly depending on those factors.[1] Computerized models are available to predict survival.[2] With best treatment and dependent on staging, 10-year disease-free survival varies from 98% to 10%. Treatment includes surgery, drugs (hormonal therapy and chemotherapy), and radiation.

Worldwide, breast cancer comprises 10.4% of all cancer incidence among women, making it the second most common type of non-skin cancer (after lung cancer) and the fifth most common cause of cancer death.[3] In 2004, breast cancer caused 519,000 deaths worldwide (7% of cancer deaths; almost 1% of all deaths).[4] Breast cancer is about 100 times more common in women than in men, although males tend to have poorer outcomes due to delays in diagnosis.[5][6][7][8]

Some breast cancers require the hormones estrogen and progesterone to grow, and have receptors for those hormones. After surgery those cancers are treated with drugs that interfere with those hormones, usually tamoxifen, and with drugs that shut off the production of estrogen in the ovaries or elsewhere; this may damage the ovaries and end fertility. After surgery, low-risk, hormone-sensitive breast cancers may be treated with hormone therapy and radiation alone. Breast cancers without hormone receptors, or which have spread to the lymph nodes in the armpits, or which express certain genetic characteristics, are higher-risk, and are treated more aggressively. One standard regimen, popular in the U.S., is cyclophosphamide plus doxorubicin (Adriamycin), known as CA; these drugs damage DNA in the cancer, but also in fast-growing normal cells where they cause serious side effects. Sometimes a taxane drug, such as docetaxel, is added, and the regime is then known as CAT; taxane attacks the microtubules in cancer cells. An equivalent treatment, popular in Europe, is cyclophosphamide, methotrexate, and fluorouracil (CMF).[9] Monoclonal antibodies, such as trastuzumab (Herceptin), are used for cancer cells that have the HER2 mutation. Radiation is usually added to the surgical bed to control cancer cells that were missed by the surgery, which usually extends survival, although radiation exposure to the heart may cause damage and heart failure in the following years.[10]

Contents

Classification

Breast cancers can be classified by different schemata. Every aspect influences treatment response and prognosis. Description of a breast cancer would optimally include multiple classification aspects, as well as other findings, such as signs found on physical exam. Classification aspects include stage (TNM), pathology, grade, receptor status, and the presence or absence of genes as determined by DNA testing:

  • Stage. The TNM classification for breast cancer is based on the size of the tumor (T), whether or not the tumor has spread to the lymph nodes (N) in the armpits, and whether the tumor has metastasized (M) (i.e. spread to a more distant part of the body). Larger size, nodal spread, and metastasis have a larger stage number and a worse prognosis.
    The main stages are:
    Stage 0 is a pre-malignant disease or marker (sometimes called DCIS: Ductal Carcinoma in Situ) .
    Stages 1–3 are defined as 'early' cancer and potentially curable.
    Stage 4 is defined as 'advanced' and/or 'metastatic' cancer and incurable.
  • Histopathology. Breast cancer is usually, but not always, primarily classified by its histological appearance. Most breast cancers are' derived from the epithelium lining the ducts or lobules, and are classified as mammary ductal carcinoma. Carcinoma in situ is proliferation of cancer cells within the epithelial tissue without invasion of the surrounding tissue. In contrast, invasive carcinoma invades the surrounding tissue.[11]
  • Grade (Bloom-Richardson grade). When cells become differentiated, they take different shapes and forms to function as part of an organ. Cancerous cells lose that differentiation. In cancer grading, tumor cells are generally classified as well differentiated (low grade), moderately differentiated (intermediate grade), and poorly differentiated (high grade). Poorly differentiated cancers have a worse prognosis.
  • Receptor status. Cells have receptors on their surface and in their cytoplasm and nucleus. Chemical messengers such as hormones bind to receptors, and this causes changes in the cell. Breast cancer cells may or may not have three important receptors: estrogen receptor (ER), progesterone receptor (PR), and HER2/neu. Cells with none of these receptors are called basal-like or triple negative. ER+ cancer cells depend on estrogen for their growth, so they can be treated with drugs to block estrogen effects (e.g. tamoxifen), and generally have a better prognosis.
    Generally, HER2+ had a worse prognosis,[12] however HER2+ cancer cells respond to drugs such as the monoclonal antibody, trastuzumab, (in combination with conventional chemotherapy) and this has improved the prognosis significantly.[13]
  • DNA microarrays have compared normal cells to breast cancer cells and found differences in hundreds of genes, but the significance of most of those differences is unknown.

Signs and symptoms

Breast cancer showing an inverted nipple, lump, skin dimpling

The first noticeable symptom of breast cancer is typically a lump that feels different from the rest of the breast tissue. More than 80% of breast cancer cases are discovered when the woman feels a lump.[14] By the time a breast lump is noticeable, it has probably been growing for years. The earliest breast cancers are detected by a mammogram.[15] Lumps found in lymph nodes located in the armpits[14] can also indicate breast cancer.

Indications of breast cancer other than a lump may include changes in breast size or shape, skin dimpling, nipple inversion, or spontaneous single-nipple discharge. Pain ("mastodynia") is an unreliable tool in determining the presence or absence of breast cancer, but may be indicative of other breast health issues.[14][15][16]

When breast cancer cells invade the dermal lymphatics—small lymph vessels in the skin of the breast—its presentation can resemble skin inflammation and thus is known as inflammatory breast cancer (IBC). Symptoms of inflammatory breast cancer include pain, swelling, warmth and redness throughout the breast, as well as an orange-peel texture to the skin referred to as peau d'orange.[14]

Another reported symptom complex of breast cancer is Paget's disease of the breast. This syndrome presents as eczematoid skin changes such as redness and mild flaking of the nipple skin. As Paget's advances, symptoms may include tingling, itching, increased sensitivity, burning, and pain. There may also be discharge from the nipple. Approximately half of women diagnosed with Paget's also have a lump in the breast.[17]

Occasionally, breast cancer presents as metastatic disease, that is, cancer that has spread beyond the original organ. Metastatic breast cancer will cause symptoms that depend on the location of metastasis. Common sites of metastasis include bone, liver, lung and brain.[18] Unexplained weight loss can occasionally herald an occult breast cancer, as can symptoms of fevers or chills. Bone or joint pains can sometimes be manifestations of metastatic breast cancer, as can jaundice or neurological symptoms. These symptoms are "non-specific", meaning they can also be manifestations of many other illnesses.[19]

Most symptoms of breast disorder do not turn out to represent underlying breast cancer. Benign breast diseases such as mastitis and fibroadenoma of the breast are more common causes of breast disorder symptoms. The appearance of a new symptom should be taken seriously by both patients and their doctors, because of the possibility of an underlying breast cancer at almost any age.[20]

Risk factors

The primary risk factors that have been identified are sex,[21] age,[22] lack of childbearing or breastfeeding,[23][24] and higher hormone levels,[25][26].

In a study published in 1995, well-established risk factors accounted for 47% of cases while only 5% were attributable to hereditary syndromes.[27] Genetic factors usually increase the risk slightly or moderately; the exception is women and men who are carriers of BRCA mutations. These people have a very high lifetime risk for breast and ovarian cancer, depending on the portion of the proteins where the mutation occurs. Instead of a 12 percent lifetime risk of breast cancer, women with one of these genes has a risk of approximately 60 percent.[28] In more recent years, research has indicated the impact of diet and other behaviors on breast cancer. These additional risk factors include a high-fat diet,[29] alcohol intake,[30][31] obesity,[32] and environmental factors such as tobacco use, radiation,[33] endocrine disruptors and shiftwork.[34] Although the radiation from mammography is a low dose, the cumulative effect can cause cancer.[35] [36]

In addition to the risk factors specified above, demographic and medical risk factors include:

  • Personal history of breast cancer: A woman who had breast cancer in one breast has an increased risk of getting cancer in her other breast.
  • Family history: A woman's risk of breast cancer is higher if her mother, sister, or daughter had breast cancer. The risk is higher if her family member got breast cancer before age 40. Having other relatives with breast cancer (in either her mother's or father's family) may also increase a woman's risk.
  • Certain breast changes: Some women have cells in the breast that look abnormal under a microscope. Having certain types of abnormal cells (atypical hyperplasia and lobular carcinoma in situ [LCIS]) increases the risk of breast cancer.
  • Race: Breast cancer is diagnosed more often in women of European ancestry than those of African or Asian ancestry.

A National Cancer Institute (NCI) study of 72,000 women found that those who had a normal body mass index at age 20 and gained weight as they aged had nearly double the risk of developing breast cancer after menopause in comparison to women maintained their weight. The average 60 year-old woman's risk of developing breast cancer by age 65 is about 2 percent; her lifetime risk is 13 percent.[37]

Abortion has not been found to be a risk factor for breast cancer. The breast cancer abortion hypothesis, however, continues to be promoted by some pro-life groups.[38][39][40]

The United Kingdom is the member of International Cancer Genome Consortium that is leading efforts to map breast cancer's complete genome.

Pathophysiology

File:Signal transduction v1.png
Overview of signal transduction pathways involved in apoptosis. Mutations leading to loss of apoptosis can lead to tumorigenesis.

Breast cancer, like other cancers, occurs because of an interaction between the environment and a defective gene. Normal cells divide as many times as needed and stop. They attach to other cells and stay in place in tissues. Cells become cancerous when mutations destroy their ability to stop dividing, to attach to other cells and to stay where they belong. When cells divide, their DNA is normally copied with many mistakes. Error-correcting proteins fix those mistakes. The mutations known to cause cancer, such as p53, BRCA1 and BRCA2, occur in the error-correcting mechanisms. These mutations are either inherited or acquired after birth. Presumably, they allow the other mutations, which allow uncontrolled division, lack of attachment, and metastasis to distant organs.[33][41] Normal cells will commit cell suicide (apoptosis) when they are no longer needed. Until then, they are protected from cell suicide by several protein clusters and pathways. One of the protective pathways is the PI3K/AKT pathway; another is the RAS/MEK/ERK pathway. Sometimes the genes along these protective pathways are mutated in a way that turns them permanently "on", rendering the cell incapable of committing suicide when it is no longer needed. This is one of the steps that causes cancer in combination with other mutations. Normally, the PTEN protein turns off the PI3K/AKT pathway when the cell is ready for cell suicide. In some breast cancers, the gene for the PTEN protein is mutated, so the PI3K/AKT pathway is stuck in the "on" position, and the cancer cell does not commit suicide.[42]

Mutations that can lead to breast cancer have been experimentally linked to estrogen exposure.[43]

Failure of immune surveillance, the removal of malignant cells throughout one's life by the immune system.[44]

Abnormal growth factor signaling in the interaction between stromal cells and epithelial cells can facilitate malignant cell growth.[45][46]

People in less-developed countries report lower incidence rates than in developed countries.[citation needed]

In the United States, 10 to 20 percent of patients with breast cancer and patients with ovarian cancer have a first- or second-degree relative with one of these diseases. Mutations in either of two major susceptibility genes, breast cancer susceptibility gene 1 (BRCA1) and breast cancer susceptibility gene 2 (BRCA2), confer a lifetime risk of breast cancer of between 60 and 85 percent and a lifetime risk of ovarian cancer of between 15 and 40 percent. However, mutations in these genes account for only 2 to 3 percent of all breast cancers.[47]

Diagnosis

Template:Unreferenced While screening techniques (which are further discussed below) are useful in determining the possibility of cancer, a further testing is necessary to confirm whether a lump detected on screening is cancer, as opposed to a benign alternative such as a simple cyst.

In a clinical setting, breast cancer is commonly diagnosed using a "triple test" of clinical breast examination (breast examination by a trained medical practitioner), mammography, and fine needle aspiration cytology. Both mammography and clinical breast exam, also used for screening, can indicate an approximate likelihood that a lump is cancer, and may also identify any other lesions. Fine Needle Aspiration and Cytology (FNAC), which may be done in a GP's office using local anaesthetic if required, involves attempting to extract a small portion of fluid from the lump. Clear fluid makes the lump highly unlikely to be cancerous, but bloody fluid may be sent off for inspection under a microscope for cancerous cells. Together, these three tools can be used to diagnose breast cancer with a good degree of accuracy.

Other options for biopsy include core biopsy, where a section of the breast lump is removed, and an excisional biopsy, where the entire lump is removed.

In addition vacuum-assisted breast biopsy (VAB) may help diagnose breast cancer among patients with a mammographically detected breast in women according to a systematic review .[48] In this study, summary estimates for vacuum assisted breast biopsy in diagnosis of breast cancer were as follows sensitivity was 98.1% with 95% CI = 0.972-0.987 and specificity was 100% with 95% CI = 0.997-0.999. However underestimate rates of atypical ductal hyperplasia (ADH) and ductal carcinoma in situ (DCIS) were 20.9% with 95% CI =0.177-0.245 and 11.2% with 95% CI = 0.098-0.128 respectively.

Screening

Breast cancer screening refers to testing otherwise-healthy women for breast cancer in an attempt to achieve an earlier diagnosis. The assumption is that early detection will improve outcomes. A number of screening test have been employed including: clinical and self breast exams, mammography, genetic screening, ultrasound, and magnetic resonance imaging.

A clinical or self breast exam involves feeling the breast for lumps or other abnormalities. Research evidence does not support the effectiveness of either type of breast exam, because by the time a lump is large enough to be found it is likely to have been growing for several years and will soon be large enough to be found without an exam.[49] Mammographic screening for breast cancer uses x-rays to examine the breast for any uncharacteristic masses or lumps. The Cochrane collaboration in 2009 concluded that mammograms reduce mortality from breast cancer by 15 percent but also result in unnecessary surgery and anxiety, resulting in their view that mammography screening may do more harm than good.[50] Many national organizations recommend regular mammography, nevertheless. For the average woman, the U.S. Preventive Services Task Force recommends mammography every two years in women between the ages of 50 and 74.[51] The Task Force points out that in addition to unnecessary surgery and anxiety, the risks of more frequent mammograms include a small but significant increase in breast cancer induced by radiation.[52]

In women at high risk, such as those with a strong family history of cancer, mammography screening is recommended at an earlier age and additional testing may include genetic screening that tests for the BRCA genes and / or magnetic resonance imaging.

Treatment

Breast cancer is sometimes treated first with surgery, and then with chemotherapy, radiation, or both. Treatments are given with increasing aggressiveness according to the prognosis and risk of recurrence.
Stage 1 cancers (and DCIS) have an excellent prognosis and are generally treated with lumpectomy with or without chemotherapy or radiation.[53] Although the aggressive HER2+ cancers should also be treated with the trastuzumab (Herceptin) regime.[54]
Stage 2 and 3 cancers with a progressively poorer prognosis and greater risk of recurrence are generally treated with surgery (lumpectomy or mastectomy with or without lymph node removal), radiation (sometimes) and chemotherapy (plus trastuzumab for HER2+ cancers).
Stage 4, metastatic cancer, (i.e. spread to distant sites) is not curable and is managed by various combinations of all treatments from surgery, radiation, chemotherapy and targeted therapies. These treatments increase the median survival time of stage 4 breast cancer by about 6 months.[55]

Medications

Drugs used after and in addition to surgery are called adjuvant therapy. Chemotherapy prior to surgery is called neo-adjuvant therapy. There are currently 3 main groups of medications used for adjuvant breast cancer treatment:

  • Hormone Blocking Therapy
  • Chemotherapy
  • Monoclonal Antibodies

One or all of these groups can be used.

Hormone Blocking Therapy: Some breast cancers require estrogen to continue growing. They can be identified by the presence of estrogen receptors (ER+) and progesterone receptors (PR+) on their surface (sometimes referred to together as hormone receptors, HR+). These ER+ cancers can be treated with drugs that either block the receptors, such as tamoxifen, or alternatively block the production of estrogen, such as the aromatase inhibitor, anastrozole (Arimidex).

Chemotherapy: Usually used for stage 1-4 disease. They are given in combinations. One of the most common treatments is cyclophosphamide plus doxorubicin (Adriamycin), known as AC; these drugs damage DNA in the cancer, but also in fast-growing normal cells where they cause serious side effects. Damage to the heart muscle is the most dangerous complication of doxorubicin. Sometimes a taxane drug, such as docetaxel, is added, and the regime is then known as CAT; taxane attacks the microtubules in cancer cells. Another common treatment, which produces equivalent results, is cyclophosphamide, methotrexate, and fluorouracil (CMF). (Chemotherapy can literally refer to any drug, but it is usually used to refer to traditional non-hormone treatments for cancer.)

Monoclonal antibodies: A relatively recent and very exciting development in HER2+ breast cancer treatment. Cancer cells have a receptor called HER2 on their surface. This receptor is normally stimulated by a growth factor which causes the cell to divide, however in the absence of the growth factor, the cell will normally stop growing. In approx 20% of invasive breast cancers, the HER2 receptor is stuck in the "on" position. The cell divides without stopping, producing an aggressive form of cancer. Trastuzumab (Herceptin), a monoclonal antibody to HER2, has dramatically improved the 5yr disease free survival of 'early' (stages 1–3) HER2+ breast cancers to about 87%.[56] Trastuzumab, however, is expensive, and approx 2% of patients suffer significant heart damage; it is otherwise well tolerated with far milder side effects than conventional chemotherapy.[57] Other monoclonal antibodies are also being trialled.

Finally, a recent article has claimed that Aspirin may reduce mortality from breast cancer.[58]

Radiation

Radiotherapy is given after surgery to the region of the tumor bed, to destroy microscopic tumors that may have escaped surgery. It may also have a beneficial effect on tumour microenvironment[59][60]. . Radiation therapy can be delivered as external beam radiotherapy or as brachytherapy (internal radiotherapy). Conventionally radiotherapy is given after the operation for breast cancer. Radiation can also be given, arguably more efficiently, at the time of operation on the breast cancer- intraoperatively. The largest randomised trial to test this approach was the TARGIT-A Trial which found that targeted intraoperative radiotherapy was equally effective at 4-years as the usual several weeks' of whole breast external beam radiotherapy [2] . Radiation can reduce the risk of recurrence by 50-66% (1/2 - 2/3rds reduction of risk) when delivered in the correct dose[61] and is considered essential when breast cancer is treated by removing only the lump (Lumpectomy or Wide local excision)

Prognosis

A prognosis is a prediction of outcome, usually the probability of death (or survival), and the probability of progression-free survival (PFS) or disease-free survival (DFS). These predictions are based on experience with breast cancer patients with similar classification. A prognosis is an estimate, as patients with the same classification will survive a different amount of time, and classifications are not always precise. Survival is usually calculated as an average number of months (or years) that 50% of patients survive, or the percentage of patients that are alive after 1, 5, 15 and 20 years. Prognosis is important for treatment decisions because patients with a good prognosis are usually offered less invasive treatments, such as lumpectomy and radiation or hormone therapy, while patients with poor prognosis are usually offered more aggressive treatment, such as more extensive mastectomy and one or more chemotherapy drugs.

Prognostic factors include staging, (i.e., tumor size, location, grade, whether disease has traveled to other parts of the body), recurrence of the disease, and age of patient.

Stage is the most important, as it takes into consideration size, local involvement, lymph node status and whether metastatic disease is present. The higher the stage at diagnosis, the worse the prognosis. The stage is raised by the invasiveness of disease to lymph nodes, chest wall, skin or beyond, and the aggressiveness of the cancer cells. The stage is lowered by the presence of cancer-free zones and close-to-normal cell behaviour (grading). Size is not a factor in staging unless the cancer is invasive. For example, Ductal Carcinoma In Situ (DCIS) involving the entire breast will still be stage zero and consequently an excellent prognosis with a 10yr disease free survival of about 98%.[62]

Grading is based on how biopsied, cultured cells behave. The closer to normal cancer cells are, the slower their growth and the better the prognosis. If cells are not well differentiated, they will appear immature, will divide more rapidly, and will tend to spread. Well differentiated is given a grade of 1, moderate is grade 2, while poor or undifferentiated is given a higher grade of 3 or 4 (depending upon the scale used).

Younger women tend to have a poorer prognosis than post-menopausal women due to several factors. Their breasts are active with their cycles, they may be nursing infants, and may be unaware of changes in their breasts. Therefore, younger women are usually at a more advanced stage when diagnosed. There may also be biologic factors contributing to a higher risk of disease recurrence for younger women with breast cancer.[63]

The presence of estrogen and progesterone receptors in the cancer cell is important in guiding treatment. Those who do not test positive for these specific receptors will not be able to respond to hormone therapy, and this can affect their chance of survival depending upon what treatment options remain, the exact type of the cancer, and how advanced the disease is.

In addition to hormone receptors, there are other cell surface proteins that may affect prognosis and treatment. HER2 status directs the course of treatment. Patients whose cancer cells are positive for HER2 have more aggressive disease and may be treated with the 'targeted therapy', trastuzumab (Herceptin), a monoclonal antibody that targets this protein and improves the prognosis significantly. Tumors overexpressing the Wnt signaling pathway co-receptor low-density lipoprotein receptor-related protein 6 (LRP6) may represent a distinct subtype of breast cancer and a potential treatment target.[64]

Psychological aspects

The emotional impact of cancer diagnosis, symptoms, treatment, and related issues can be severe. Most larger hospitals are associated with cancer support groups which provide a supportive environment to help patients cope and gain perspective from cancer survivors. Online cancer support groups are also very beneficial to cancer patients, especially in dealing with uncertainty and body-image problems inherent in cancer treatment.

Not all breast cancer patients experience their illness in the same manner. Factors such as age can have a significant impact on the way a patient copes with a breast cancer diagnosis. Premenopausal women with estrogen-receptor positive breast cancer must confront the issues of early menopause induced by many of the chemotherapy regimens used to treat their breast cancer, especially those that use hormones to counteract ovarian function.[65]

On the other hand, a recent study conducted by researchers at the College of Public Health of the University of Georgia showed that older women may face a more difficult recovery from breast cancer than their younger counterparts.[66] As the incidence of breast cancer in women over 50 rises and survival rates increase, breast cancer is increasingly becoming a geriatric issue that warrants both further research and the expansion of specialized cancer support services tailored for specific age groups.[66]

Epidemiology

File:Breast cancer world map - Death - WHO2004.svg
Age-standardized death from breast cancer per 100,000 inhabitants in 2004.[67]
     no data      less than 2      2-4      4-6      6-8      8-10      10-12      12-14      14-16      16-18      18-20      20-22      more than 22

Worldwide, breast cancer is the most common cancer in women, after skin cancer, representing 16% of all female cancers.[68] The rate is more than twice that of colorectal cancer and cervical cancer and about three times that of lung cancer.[citation needed] Mortality worldwide is 25% greater than that of lung cancer in women.[3] In 2004, breast cancer caused 519,000 deaths worldwide (7% of cancer deaths; almost 1% of all deaths).[4] The number of cases worldwide has significantly increased since the 1970s, a phenomenon partly attributed to the modern lifestyles.[69][70]

The incidence of breast cancer varies greatly around the world: it is lowest in less-developed countries and greatest in the more-developed countries. In the twelve world regions, the annual age-standardized incidence rates per 100,000 women are as follows: in Eastern Asia, 18; South Central Asia, 22; sub-Saharan Africa, 22; South-Eastern Asia, 26; North Africa and Western Asia, 28; South and Central America, 42; Eastern Europe, 49; Southern Europe, 56; Northern Europe, 73; Oceania, 74; Western Europe, 78; and in North America, 90.[71]

Breast cancer is strongly related to age with only 5% of all breast cancers occur in women under 40 years old.[72] However, it can occur in younger women.

United States

The lifetime risk for breast cancer in the United States is usually given as 1 in 8 (12.5%) with a 1 in 35 (3%) chance of death.[73] A recent analysis however has called this estimate into question when it found a risk of only 6% in healthy women.[74]

The United States has the highest annual incidence rates of breast cancer in the world; 128.6 per 100,000 in whites and 112.6 per 100,000 among African Americans.[73][75] It is the second-most common cancer (after skin cancer) and the second-most common cause of cancer death (after lung cancer).[73] In 2007, breast cancer was expected to cause 40,910 deaths in the US (7% of cancer deaths; almost 2% of all deaths).[15] This figure includes 450-500 annual deaths among men out of 2000 cancer cases.[76]

In the US, both incidence and death rates for breast cancer have been declining in the last few years in Native Americans and Alaskan Natives.[15][77] Nevertheless, a US study conducted in 2005 indicated that breast cancer remains the most feared disease,[78] even though heart disease is a much more common cause of death among women.[79] Many doctors say that women exaggerate their risk of breast cancer.[80]

Racial disparities

Several studies have found that black women in the U.S. are more likely to die from breast cancer even though white women are more likely to be diagnosed with the disease. Even after diagnosis, black women are less likely to get treatment compared to white women.[81][82][83] Scholars have advanced several theories for the disparities, including inadequate access to screening, reduced availability of the most advanced surgical and medical techniques, or some biological characteristic of the disease in the African American population.[84] Some studies suggest that the racial disparity in breast cancer outcomes may reflect cultural biases more than biological disease differences.[85] However, the lack of diversity in clinical trials for breast cancer treatment may contribute to these disparities, with recent research indicating that black women are more likely to have estrogen receptor negative breast cancers, which are not responsive to hormone treatments that are effective for most white women.[86] Research is currently ongoing to define the contribution of both biological and cultural factors.[82][87]

UK

45,000 cases diagnosed and 12,500 deaths per annum. 60% of cases are treated with Tamoxifen, of these the drug becomes ineffective in 35%.[88]

Developing countries

As developing countries grow and adopt Western culture they also accumulate more disease that has arisen from Western culture and its habits (fat/alcohol intake, smoking, exposure to oral contraceptives, the changing patterns of childbearing and breastfeeding, low parity). For instance, as South America has developed so has the amount of breast cancer. "Breast cancer in less developed countries, such as those in South America, is a major public health issue. It is a leading cause of cancer-related deaths in women in countries such as Argentina, Uruguay, and Brazil. The expected numbers of new cases and deaths due to breast cancer in South America for the year 2001 are approximately 70,000 and 30,000, respectively." [89] However, because of a lack of funding and resources, treatment is not always available to those suffering with breast cancer.

History

File:Louis-Jacques Goussier Enzyklopädie Diderot Pl XXIX.jpg
Breast cancer surgery in the 18th century

Breast cancer may be one of the oldest known forms of cancerous tumors in humans. The oldest description of cancer was discovered in Egypt and dates back to approximately 1600 BC. The Edwin Smith Papyrus describes 8 cases of tumors or ulcers of the breast that were treated by cauterization. The writing says about the disease, "There is no treatment."[90] For centuries, physicians described similar cases in their practises, with the same conclusion. It was not until doctors achieved greater understanding of the circulatory system in the 17th century that they could establish a link between breast cancer and the lymph nodes in the armpit. The French surgeon Jean Louis Petit (1674–1750) and later the Scottish surgeon Benjamin Bell (1749–1806) were the first to remove the lymph nodes, breast tissue, and underlying chest muscle. Their successful work was carried on by William Stewart Halsted who started performing mastectomies in 1882. The Halsted radical mastectomy often involved removing both breasts, associated lymph nodes, and the underlying chest muscles. This often led to long-term pain and disability, but was seen as necessary in order to prevent the cancer from recurring.[91] Radical mastectomies remained the standard until the 1970s, when a new understanding of metastasis led to perceiving cancer as a systemic illness as well as a localized one, and more sparing procedures were developed that proved equally effective.

The French surgeon Bernard Peyrilhe (1737–1804) realized the first experimental transmission of cancer by injecting extracts of breast cancer into an animal.

Prominent women who died of breast cancer include Empress Theodora, wife of Justinian; Anne of Austria, mother of Louis XIV of France; Mary Washington, mother of George, and Rachel Carson, the environmentalist.[92]

The first case-controlled study on breast cancer epidemiology was done by Janet Lane-Claypon, who published a comparative study in 1926 of 500 breast cancer cases and 500 control patients of the same background and lifestyle for the British Ministry of Health.[93][verification needed][94]

Society and culture

File:Pink ribbon.svg
A pink ribbon, the universal symbol of breast cancer awareness.

The widespread acceptance of second opinions before surgery, less invasive surgical procedures, support groups, and other advances in patient care have stemmed, in part, from the breast cancer advocacy movement.[95]

October is recognized as National Breast Cancer Awareness Month by the media as well as survivors, family and friends of survivors and/or victims of the disease.[96] A pink ribbon is worn to recognize the struggle that sufferers face when battling with the cancer.[97] On the meaning of this, see Semiotics of breast cancer pink ribbon.

The patron saint of breast cancer is Agatha of Sicily.[98]

In the fall of 1991, Susan G. Komen for the Cure handed out pink ribbons to participants in its New York City race for breast cancer survivors.[99]

The pink and blue ribbon was designed in 1996 by Nancy Nick, President and Founder of the John W. Nick Foundation to bring awareness that "Men Get Breast Cancer Too!"[100]

In 2009 the male breast cancer advocacy groups Out of the Shadow of Pink, A Man's Pink and the Brandon Greening Foundation for Breast Cancer in Men joined together to globally establish the third week of October as "Male Breast Cancer Awareness Week"[101]

In the first quarter of 2009, Anthony L. May the President and Founder of Men For A Cause, United Against Breast Cancer created the very symbolic Official Breast Cancer Awareness Flag to advocate year around breast cancer awareness."[102]

Art

Possible breast cancer signs in historical paintings have been repeatedly discussed in medical literature. A typical lump, differences in breast size or shape and the peau d'orange can be found for example in works by Raphael, Rembrandt and Rubens.[103][104][105][106] However if the visible changes are really dealing with breast cancer can not be proved and was therefore doubted.[107]

Cell lines for research

A considerable part of the current knowledge on breast carcinomas is based on in vivo and in vitro studies performed with breast cancer cell (BCC) lines. These provide an unlimited source of homogenous self-replicating material, free of contaminating stromal cells, and often easily cultured in simple standard media. The first line described, BT-20, was established in 1958. Since then, and despite sustained work in this area, the number of permanent lines obtained has been strikingly low (about 100). Indeed, attempts to culture BCC from primary tumors have been largely unsuccessful. This poor efficiency was often due to technical difficulties associated with the extraction of viable tumor cells from their surrounding stroma. Most of the available BCC lines issued from metastatic tumors, mainly from pleural effusions. Effusions provided generally large numbers of dissociated, viable tumor cells with little or no contamination by fibroblasts and other tumor stroma cells. Many of the currently used BCC lines were established in the late 1970s. A very few of them, namely MCF-7, T-47D, and MDA-MB-231, account for more than two-thirds of all abstracts reporting studies on mentioned BCC lines, as concluded from a Medline-based survey.

Treatments are constantly evaluated in randomized, controlled trials, to evaluate and compare individual drugs, combinations of drugs, and surgical and radiation techniques. The latest research is reported annually at scientific meetings such as that of the American Society of Clinical Oncology, San Antonio Breast Cancer Symposium,[108] and the St. Gallen Oncology Conference in St. Gallen, Switzerland.[109] These studies are reviewed by professional societies and other organizations, and formulated into guidelines for specific treatment groups and risk category.

List of cell lines

Mainly based on Lacroix and Leclercq (2004).[110] For more data on the nature of TP53 mutations in breast cancer cell lines, see Lacroix et al. (2006).[111]

Template:Dynamic list

Cell line Primary tumor Origin of cells Estrogen receptors Progesterone receptors ERBB2 amplification Mutated TP53 Tumorigenic in mice Reference
600MPE Invasive ductal carcinoma + - - [112]
AU565 Adenocarcinoma - - + - [112]
BT-20 Invasive ductal carcinoma Primary No No No Yes Yes [113]
BT-474 Invasive ductal carcinoma Primary Yes Yes Yes Yes Yes [114]
BT-483 Invasive ductal carcinoma + + - [112]
BT-549 Invasive ductal carcinoma - - + [112]
Evsa-T Invasive ductal carcinoma, mucin-producing, signet-ring type Metastasis (ascites) No Yes  ? Yes  ? [115]
Hs578T Carcinosarcoma Primary No No No Yes No [116]
MCF-7 Invasive ductal carcinoma Metastasis (pleural effusion) Yes Yes No No (wild-type) Yes (with estrogen supplementation) [117]
MDA-MB-231 Invasive ductal carcinoma Metastasis (pleural effusion) No No No Yes Yes [118]
SK-BR-3 Invasive ductal carcinoma Metastasis (pleural effusion) No No Yes Yes No [119]
T-47D Invasive ductal carcinoma Metastasis (pleural effusion) Yes Yes No Yes Yes (with estrogen supplementation) [120]

See also

References

  1. "Merck Manual Online, Breast Cancer". http://www.merck.com/mmpe/print/sec18/ch253/ch253e.html. 
  2. CancerMath.net Calculates survival with breast cancer based on prognostic factors and treatment. From the Laboratory for Quantitative Medicine, Massachusetts General Hospital.
  3. 3.0 3.1 "World Cancer Report". International Agency for Research on Cancer. June 2003. http://www.iarc.fr/en/Publications/PDFs-online/World-Cancer-Report/World-Cancer-Report. Retrieved 2009-03-26. 
  4. 4.0 4.1 "Fact sheet No. 297: Cancer". World Health Organization. February 2006. http://www.who.int/mediacentre/factsheets/fs297/en/index.html. Retrieved 2009-03-26. 
  5. "Male Breast Cancer Treatment". National Cancer Institute. 2006. http://www.cancer.gov/cancertopics/pdq/treatment/malebreast/healthprofessional. Retrieved 2006-10-16. 
  6. "Breast Cancer in Men". Cancer Research UK. 2007. http://www.cancerhelp.org.uk/help/default.asp?page=5075. Retrieved 2007-11-06. 
  7. "What Are the Key Statistics About Breast Cancer in Men?". American Cancer Society. September 27, 2007. http://www.cancer.org/docroot/CRI/content/CRI_2_4_1X_What_are_the_key_statistics_for_male_breast_cancer_28.asp?sitearea=. Retrieved 2008-02-03. 
  8. "ACS :: What Are the Key Statistics About Breast Cancer in Men?". Cancer.org. http://www.cancer.org/docroot/CRI/content/CRI_2_4_1X_What_are_the_key_statistics_for_male_breast_cancer_28.asp?sitearea=. Retrieved 2010-05-08. 
  9. Muss HB, Berry DA, Cirrincione CT, et al. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med. 2009 May 14;360(20):2055-65.
  10. Buchholz TA. N Engl J Med. 2009 Jan 1;360(1):63-70. Radiation therapy for early-stage breast cancer after breast-conserving surgery.
  11. Merck Manual, Professional Edition, Ch. 253, Breast Cancer.
  12. Molecular origin of cancer: gene-expression signatures in breast cancer, Christos Sotirou and Lajos Pusztai, N Engl J Med 360:790 (2009 Feb 19)
  13. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2+ breast cancer. N Engl J Med. 2005; 353:1673-1684 and supplementary appendix.
  14. 14.0 14.1 14.2 14.3 Merck Manual of Diagnosis and Therapy (February 2003). "Breast Disorders: Cancer". http://www.merck.com/mmhe/sec22/ch251/ch251f.html#sec22-ch251-ch251f-525. Retrieved 2008-02-05. 
  15. 15.0 15.1 15.2 15.3 American Cancer Society (2007). "Cancer Facts & Figures 2007" (PDF). http://www.cancer.org/downloads/STT/CAFF2007PWSecured.pdf. Retrieved 2007-04-26. 
  16. eMedicine (August 23, 2006). "Breast Cancer Evaluation". http://www.emedicine.com/med/TOPIC3287.HTM. Retrieved 2008-02-05. 
  17. National Cancer Institute (June 27, 2005). "Paget's Disease of the Nipple: Questions and Answers". http://www.cancer.gov/cancertopics/factsheet/Sites-Types/pagets-breast. Retrieved 2008-02-06. 
  18. Lacroix M (December 2006). [Expression error: Missing operand for > "Significance, detection and markers of disseminated breast cancer cells"]. Endocrine-related Cancer 13 (4): 1033–67. doi:10.1677/ERC-06-0001. PMID 17158753. 
  19. National Cancer Institute (September 1, 2004). "Metastatic Cancer: Questions and Answers". http://www.cancer.gov/cancertopics/factsheet/Sites-Types/metastatic. Retrieved 2008-02-06. 
  20. Merck Manual of Diagnosis and Therapy (February 2003). "Breast Disorders: Introduction". http://www.merck.com/mmhe/sec22/ch251/ch251a.html. Retrieved 2008-02-05. 
  21. Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN (July 2004). [Expression error: Missing operand for > "Breast carcinoma in men: a population-based study"]. Cancer 101 (1): 51–7. doi:10.1002/cncr.20312. PMID 15221988. 
  22. "Breast Cancer Risk Factors". 2008-11-25. http://www.breastcancer.org/symptoms/understand_bc/risk/factors.jsp. Retrieved 2009-11-10. 
  23. Collaborative Group on Hormonal Factors in Breast Cancer (August 2002). [Expression error: Missing operand for > "Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease."]. Lancet 360 (9328): 187–95. doi:10.1016/S0140-6736(02)09454-0. PMID 12133652. 
  24. France de Bravo B, and Zuckerman D (October 2009). "5 Ways You Can Cut your Risk of Breast Cancer". National Research Center for Women & Families. http://www.stopcancerfund.org/posts/65. 
  25. Yager JD; Davidson NE (2006). [Expression error: Missing operand for > "Estrogen carcinogenesis in breast cancer"]. New Engl J Med 354 (3): 270–82. doi:10.1056/NEJMra050776. PMID 16421368. 
  26. Santoro, E., DeSoto, M., and Hong Lee, J (February 2009). "Hormone Therapy and Menopause". National Research Center for Women & Families. http://www.center4research.org/2010/03/hormone-therapy-and-menopause/. 
  27. Madigan MP, Ziegler RG, Benichou J, Byrne C, Hoover RN (November 1995). [Expression error: Missing operand for > "Proportion of breast cancer cases in the United States explained by well-established risk factors"]. Journal of the National Cancer Institute 87 (22): 1681–5. doi:10.1093/jnci/87.22.1681. PMID 7473816. 
  28. National Cancer Institute BRCA1 and BRCA2: Cancer Risk and Genetic Testing
  29. Chlebowski RT, Blackburn GL, Thomson CA, et al. (December 2006). [Expression error: Missing operand for > "Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study"]. Journal of the National Cancer Institute 98 (24): 1767–76. doi:10.1093/jnci/djj494. PMID 17179478. 
  30. Boffetta P, Hashibe M, La Vecchia C, Zatonski W, Rehm J (August 2006). [Expression error: Missing operand for > "The burden of cancer attributable to alcohol drinking"]. International Journal of Cancer 119 (4): 884–7. doi:10.1002/ijc.21903. PMID 16557583. 
  31. [1][dead link]
  32. BBC report Weight link to breast cancer risk
  33. 33.0 33.1 American Cancer Society (2005). "Breast Cancer Facts & Figures 2005-2006" (PDF). http://www.cancer.org/downloads/STT/CAFF2005BrFacspdf2005.pdf. Retrieved 2007-04-26. 
  34. WHO international Agency for Research on Cancer Press Release No. 180, December 2007.
  35. Feig SA, Hendrick RE (1997). [Expression error: Missing operand for > "Radiation risk from screening mammography of women aged 40-49 years."]. J Natl Cancer Inst Monogr 22 (22): 119–24. PMID 9709287. 
  36. >"2009 Update: When Should Women Start Regular Mammograms? 40? 50? And How Often is “Regular”?". National Research Center for Women & Families. November 2009. http://www.stopcancerfund.org/posts/211. 
  37. "Gain in Body Mass Index Increases Postmenopausal Breast Cancer Risk". National Cancer Institute. http://benchmarks.cancer.gov/2010/04/gain-in-body-mass-index-increases-postmenopausal-breast-cancer-risk. Retrieved 2010-04-26. 
  38. "WHO - Induced abortion does not increase breast cancer risk". who.int. http://www.who.int/mediacentre/factsheets/fs240/en/index.html. Retrieved 2007-12-24. 
  39. "ACS :: Can Having an Abortion Cause or Contribute to Breast Cancer?". cancer.org. http://www.cancer.org/docroot/CRI/content/CRI_2_6x_Can_Having_an_Abortion_Cause_or_Contribute_to_Breast_Cancer.asp. Retrieved 2008-03-31. 
  40. "Summary Report: Early Reproductive Events Workshop - National Cancer Institute". cancer.gov. http://www.cancer.gov/cancerinfo/ere-workshop-report. Retrieved 2007-11-04. 
  41. Dunning AM, Healey CS, Pharoah PD, Teare MD, Ponder BA, Easton DF (1 October 1999). "A systematic review of genetic polymorphisms and breast cancer risk". Cancer Epidemiology, Biomarkers & Prevention 8 (10): 843–54. PMID 10548311. http://cebp.aacrjournals.org/cgi/pmidlookup?view=long&pmid=10548311. 
  42. "32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium". Sunday Morning Year-End Review. Dec. 14, 2009. http://www.sabcs.org/Newsletter/Docs/SABCS_2009_Issue5.pdf. 
  43. Cavalieri E, Chakravarti D, Guttenplan J, et al. (August 2006). [Expression error: Missing operand for > "Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention"]. Biochimica et Biophysica Acta 1766 (1): 63–78. doi:10.1016/j.bbcan.2006.03.001. PMID 16675129. 
  44. Farlex (2005). ">immunological surveillance "The Free Dictionary: Immunological Surveilliance". http://medical-dictionary.thefreedictionary.com/immunological+surveillance">immunological surveillance. Retrieved 2008-02-10. 
  45. Haslam SZ, Woodward TL. (June 2003). [Expression error: Missing operand for > "Host microenvironment in breast cancer development: epithelial-cell-stromal-cell interactions and steroid hormone action in normal and cancerous mammary gland."]. Breast Cancer Res. 5 (4): 208–15. doi:10.1186/bcr615. PMID 12817994. 
  46. Wiseman BS, Werb Z: Stromal effects on mammary gland development and breast cancer. Science 296:1046, 2002.
  47. "Breast and Ovarian Cancer", Richard Wooster and Barbara L. Weber, New Engl J Medicine, 348:2339-2347, June 5, 2003. (Free Full Text)
  48. Yu, YH; Liang, C; Yuan, XZ (2010). [Expression error: Missing operand for > "Diagnostic value of vacuum-assisted breast biopsy for breast carcinoma: a meta-analysis and systematic review."]. Breast cancer research and treatment 120 (2): 469–79. doi:10.1007/s10549-010-0750-1. PMID 20130983. 
  49. Kösters JP, Gøtzsche PC (2003). [Expression error: Missing operand for > "Regular self-examination or clinical examination for early detection of breast cancer"]. Cochrane Database Syst Rev (2): CD003373. doi:10.1002/14651858.CD003373. PMID 12804462. 
  50. Gøtzsche PC, Nielsen M (2009). [Expression error: Missing operand for > "Screening for breast cancer with mammography"]. Cochrane Database Syst Rev (4): CD001877. doi:10.1002/14651858.CD001877.pub3. PMID 19821284. 
  51. "Breast Cancer: Screening". United States Preventive Services Task Force. http://www.ahrq.gov/clinic/USpstf/uspsbrca.htm. 
  52. "Breast Cancer: Screening". United States Preventive Services Task Force. http://www.ahrq.gov/clinic/3rduspstf/breastCancer/brcanrr.htm#ref31. 
  53. "Surgery Choices for Women with Early Stage Breast Cancer". National Cancer Institute and the National Research Center for Women & Families. August 2004. http://www.stopcancerfund.org/wp/wp-content/uploads/2009/12/booklet04bc.pdf. 
  54. University of Texas M. D. Anderson Cancer Center (2009, November 4). Early-stage, HER2-positive Breast Cancer Patients At Increased Risk Of Recurrence. ScienceDaily. http://www.sciencedaily.com/releases/2009/11/091102172028.htm Retrieved February 7, 2010
  55. "Breast Cancer: Breast Disorders: Merck Manual Professional". Merck.com. http://www.merck.com/mmpe/sec18/ch253/ch253e.html#sec18-ch253-ch253e-572. Retrieved 2010-05-08. 
  56. Jahanzeb M (August 2008). [Expression error: Missing operand for > "Adjuvant trastuzumab therapy for HER2-positive breast cancer"]. Clin. Breast Cancer 8 (4): 324–33. doi:10.3816/CBC.2008.n.037. PMID 18757259. 
  57. "Herceptin® (trastuzumab) Adjuvant HER2+ Breast Cancer Therapy Pivotal Studies and Efficacy Data". Herceptin.com. http://www.herceptin.com/hcp/adjuvant-treatment/studies-efficacy/joint-analysis.jsp. Retrieved 2010-05-08. 
  58. "Aspirin Intake and Survival After Breast Cancer -- Holmes et al., 10.1200/JCO.2009.22.7918 -- Journal of Clinical Oncology". http://jco.ascopubs.org/cgi/content/abstract/JCO.2009.22.7918v1. 
  59. Massarut S, Baldassare G, Belleti B, Reccanello S, D'Andrea S, Ezio C, Perin T, Roncadin M, Vaidya JS (2006). "Intraoperative radiotherapy impairs breast cancer cell motility induced by surgical wound fluid". J Clin Oncol 24 (18S): 10611. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=40&abstractID=34291. 
  60. Belletti B, Vaidya JS, D'Andrea S, et al. (March 2008). "Targeted intraoperative radiotherapy impairs the stimulation of breast cancer cell proliferation and invasion caused by surgical wounding". Clin. Cancer Res. 14 (5): 1325–32. doi:10.1158/1078-0432.CCR-07-4453. PMID 18316551. http://clincancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=18316551. 
  61. Breastcancer.org Treatment Options
  62. "Breast Cancer: Breast Disorders: Merck Manual Professional". Merck.com. http://www.merck.com/mmpe/sec18/ch253/ch253e.html#sec18-ch253-ch253e-549. Retrieved 2010-05-08. 
  63. Peppercorn J (2009). "Breast Cancer in Women Under 40". Oncology 23 (6). http://www.cancernetwork.com/cme/article/10165/1413886. 
  64. Liu CC, Prior J, Piwnica-Worms D, Bu G (March 2010). [Expression error: Missing operand for > "LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy"]. Proc Natl Acad Sci U S A 107 (11): 5136–41. doi:10.1073/pnas.0911220107. PMID 20194742. 
  65. Pritchard KI (2009). "Ovarian Suppression/Ablation in Premenopausal ER-Positive Breast Cancer Patients". Oncology 23 (1). http://www.cancernetwork.com/display/article/10165/1366719?pageNumber=1. 
  66. 66.0 66.1 Robb C, Haley WE, Balducci L, et al. (April 2007). [Expression error: Missing operand for > "Impact of breast cancer survivorship on quality of life in older women"]. Critical Reviews in Oncology/hematology 62 (1): 84–91. doi:10.1016/j.critrevonc.2006.11.003. PMID 17188505. 
  67. "WHO Disease and injury country estimates". World Health Organization. 2009. http://www.who.int/healthinfo/global_burden_disease/estimates_country/en/index.html. Retrieved Nov. 11, 2009. 
  68. "Breast cancer: prevention and control". World Health Organization. http://www.who.int/cancer/detection/breastcancer/en/index1.html. 
  69. Laurance, Jeremy (2006-09-29). "Breast cancer cases rise 80% since Seventies". The Independent. http://www.independent.co.uk/life-style/health-and-wellbeing/health-news/breast-cancer-cases-rise-80-since-seventies-417990.html. Retrieved 2006-10-09. 
  70. "Breast Cancer: Statistics on Incidence, Survival, and Screening". Imaginis Corporation. 2006. http://imaginis.com/breasthealth/statistics.asp. Retrieved 2006-10-09. 
  71. Stewart B. W. and Kleihues P. (Eds): World Cancer Report. IARCPress. Lyon 2003
  72. Breast Cancer: Breast Cancer in Young Women WebMD. Retrieved on September 9, 2009
  73. 73.0 73.1 73.2 American Cancer Society (September 13, 2007). "What Are the Key Statistics for Breast Cancer?". http://www.cancer.org/docroot/CRI/content/CRI_2_4_1X_What_are_the_key_statistics_for_breast_cancer_5.asp. Retrieved 2008-02-03. 
  74. W.B. Cutler, R.E. Burki, E. Genovesse, M.G. Zacher (September 2009). "Breast cancer in postmenopausal women: what is the real risk?". Fertility and Sterility 92 (3): S16. doi:10.1016/j.fertnstert.2009.07.061. (inactive 2010-01-06). PMID 123455. http://www.sciencedirect.com/science/article/B6T6K-4X49BPB-1X/2/486c0457400ff91cb07cfb73dd2b01ce. 
  75. "Browse the SEER Cancer Statistics Review 1975-2006". http://seer.cancer.gov/csr/1975_2006/browse_csr.php?section=4&page=sect_04_table.07.html. 
  76. "Male Breast Cancer Causes, Risk Factors for Men, Symptoms and Treatment on". Medicinenet.com. http://www.medicinenet.com/male_breast_cancer/article.htm. Retrieved 2010-05-08. 
  77. Espey DK, Wu XC, Swan J, et al. (2007). [Expression error: Missing operand for > "Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska Natives"]. Cancer 110 (10): 2119–52. doi:10.1002/cncr.23044. PMID 17939129. 
  78. Template:Cite press release
  79. "Leading Causes of Death for American Women 2004" (PDF). National Heart Lung and Blood Institute. http://www.nhlbi.nih.gov/health/hearttruth/press/infograph_dressgraph.pdf. Retrieved 2007-10-15. 
  80. In Breast Cancer Data, Hope, Fear and Confusion, By DENISE GRADY, New York Times, January 26, 1999.
  81. Wisconsin Cancer Incidence and Mortality, 2000-2004 Wisconsin Department of Health and Family Services
  82. 82.0 82.1 Tammemagi CM (2007). [Expression error: Missing operand for > "Racial/ethnic disparities in breast and gynecologic cancer treatment and outcomes"]. Curr. Opin. Obstet. Gynecol. 19 (1): 31–6. doi:10.1097/GCO.0b013e3280117cf8. PMID 17218849. 
  83. Hirschman J, Whitman S, Ansell D (2007). [Expression error: Missing operand for > "The black:white disparity in breast cancer mortality: the example of Chicago"]. Cancer Causes Control 18 (3): 323–33. doi:10.1007/s10552-006-0102-y. PMID 17285262. 
  84. Breast cancer rates differ in races by Amanda Villa Wednesday, October 24, 2007. Badger Herald
  85. Benjamin M, Reddy S, Brawley OW (2003). [Expression error: Missing operand for > "Myeloma and race: a review of the literature"]. Cancer Metastasis Rev. 22 (1): 87–93. doi:10.1023/A:1022268103136. PMID 12716040. 
  86. Zuckerman, D. (2009). "The Ethics of Inclusion and Exclusion in Clinical Trials: Race, Sex, and Age". The Penn Center Guide to bioethics. (Eds:Vardit Ravitsky, Autumn Fiester, Art Caplan). Springer. ISBN 9780826115225. http://books.google.com/?id=hydXVrEWY-UC&pg=PT272&lpg=PT272&dq=The+Ethics+of+Inclusion+and+Exclusion+in+Clinical+Trials&q=The%20Ethics%20of%20Inclusion%20and%20Exclusion%20in%20Clinical%20Trials. 
  87. Demicheli R, Retsky MW, Hrushesky WJ, Baum M, Gukas ID, Jatoi I (2007). [Expression error: Missing operand for > "Racial disparities in breast cancer outcome: insights into host-tumor interactions"]. Cancer 110 (9): 1880–8. doi:10.1002/cncr.22998. PMID 17876835. 
  88. Daily Mail (UK) 13 Nov 2008
  89. (Schwartzmann, 2001, p 118)
  90. "The History of Cancer". American Cancer Society. 2002-03-25. http://www.cancer.org/docroot/CRI/content/CRI_2_6x_the_history_of_cancer_72.asp?sitearea=CRI. Retrieved 2006-10-09. 
  91. "History of Breast Cancer". Random History. 2008-02-27. http://www.randomhistory.com/1-50/029cancer.html. Retrieved 2010-05-08. 
  92. James S. Olson. Bathsheba's Breast: Women, Cancer, and History, 1st edition, The Johns Hopkins University Press, 2005 [ISBN 0-8018-8064-5. ISBN 978-0-8018-8064-3]
  93. Lane-Claypon, Janet Elizabeth (1926). A further report on cancer of the breast, with special reference to its associated antecedent conditions. London, Greater London: Her Majesty's Stationery Office (HMSO). OCLC 14713036. 
  94. Alfredo Morabia (2004). A History of Epidemiologic Methods and Concepts. Boston: Birkhauser. pp. 301–302. ISBN 3-7643-6818-7. http://books.google.com/?id=E-OZbEmPSTkC&pg=PA301&lpg=PA301&dq=%22lane+claypon%22+%22further+report+*+cancer%22. Retrieved 2007-12-31. 
  95. "History of Breast Cancer Advocacy > Personal Reflections > Bob Riter's Cancer Columns > Cancer Resource Center". Crcfl.net. http://www.crcfl.net/content/view/history-of-breast-cancer-advocacy.html. Retrieved 2010-05-08. 
  96. "Breast Cancer Awareness Month". http://www.nbcam.com/. Retrieved 2008-01-04. 
  97. "Pink Ribbon". http://pinkribbon.com/. Retrieved 2008-01-04. 
  98. "Index of Saints". Catholic Forum. http://www.catholic-forum.com/saints/sainta04.htm. Retrieved 2008-01-04. 
  99. "The Pink Ribbon Story" (PDF). http://ww5.komen.org/uploadedFiles/Content_Binaries/The_Pink_Ribbon_Story.pdf. Retrieved 2010-05-08. 
  100. "About Our Ribbon". http://www.johnwnickfoundation.org/pinkandblueribbon.html. Retrieved 2008-09-17. 
  101. "Male Breast Cancer Awareness Week". http://www.outoftheshadowofpink.com/Male-Breast-Cancer-Awareness-Week-Campaign.html. Retrieved 2009-10-01. 
  102. "Official Breast Cancer Awareness Flag". http://www.http://officialbreastcancerawarenessflag.org. Retrieved 2010-24-05. 
  103. Juan J. Grau, Jorge Estapé, Matías Diaz-Padrón: Breast cancer in Rubens paintings. Breast Cancer Res Treat. 68 (2001), 89-93, PMID 11678312, Template:DOI
  104. C. H. Espinel: The portrait of breast cancer and Raphael's La Fornarina. Lancet. 360 (2002), 2061-3, PMID 12504417
  105. Peter Allen Braithwaite, Dace Shugg: Rembrandt's Bathsheba: the dark shadow of the left breast. Ann Roy Coll Surg Engl 65 (1983), 337-8 online
  106. James Stuart Olson (2005). Bathsheba's Breast. JHU Press. ISBN 0-801-88064-5. http://books.google.com/books?doi=gp9aMBieClMC. 
  107. Adam Gross: An Epidemic of Breast Cancer Among Models of Famous Artists. Breast Cancer Res Treat. 84 (2004), 293, PMID 15026627, {{|10.1023/B:BREA.0000019965.21257.49}}
  108. San Antonio Breast Cancer Symposium Abstracts, newsletters, and other reports of the meeting.
  109. Annals of Oncology 2009 20(8):1319-1329; doi:10.1093/annonc/mdp322 Special article: Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009, A. Goldhirsch, J. N. Ingle, R. D. Gelber, et al. Review of latest research in breast cancer, as reported by expert panels at the St. Galen Oncology Conference, St. Galen, Switzerland. Free full text.
  110. Lacroix, M; Leclercq G. (2004). [Expression error: Missing operand for > "Relevance of breast cancer cell lines as models for breast tumours: an update"]. Breast Cancer Research and Treatment 83 (3): 249 – 289. doi:10.1023/B:BREA.0000014042.54925.cc. PMID 14758095. 
  111. Lacroix, M; Toillon RA, Leclercq G. (2006). [Expression error: Missing operand for > "p53 and breast cancer, an update"]. Endocrine-related cancer 13 (2): 293 – 325. doi:10.1677/erc.1.01172. PMID 16728565. 
  112. 112.0 112.1 112.2 112.3 Neve, RM; et al. (2006). [Expression error: Missing operand for > "A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes."]. Cancer Cell 10 (6): 515–527. doi:10.1016/j.ccr.2006.10.008. PMID 17157791. 
  113. Lasfargues, EY; Ozzello L. (1958). [Expression error: Missing operand for > "Cultivation of human breast carcinomas"]. Journal of the National Cancer Institute 21 (6): 1131–1147. PMID 13611537. 
  114. Lasfargues, EY; Coutinho WG, Redfield ES. (1978). [Expression error: Missing operand for > "Isolation of two human tumor epithelial cell lines from solid breast carcinomas"]. Journal of the National Cancer Institute 61 (4): 967 – 978. PMID 212572. 
  115. Borras, M; Lacroix M, Legros N, Leclercq G. (1997). [Expression error: Missing operand for > "Estrogen receptor-negative/progesterone receptor-positive Evsa-T mammary tumor cells: a model for assessing the biological property of this peculiar phenotype of breast cancers"]. Cancer Letters 120 (1): 23 – 30. doi:10.1016/S0304-3835(97)00285-1. PMID 9570382. 
  116. Hackett, AJ; Smith HS, Springer EL, Owens RB, Nelson-Rees WA, Riggs JL, Gardner MB. (1977). [Expression error: Missing operand for > "Two syngeneic cell lines from human breast tissue: the aneuploid mammary epithelial (Hs578T) and the diploid myoepithelial (Hs578Bst) cell lines"]. Journal of the National Cancer Institute 58 (6): 1795–1806. PMID 864756. 
  117. Soule, HD; Vazguez J, Long A, Albert S, Brennan M. (1973). [Expression error: Missing operand for > "A human cell line from a pleural effusion derived from a breast carcinoma"]. Journal of the National Cancer Institute 51 (5): 1409–1416. PMID 4357757. 
  118. Cailleau, R; Young R, Olivé M, Reeves WJ Jr. (1974). [Expression error: Missing operand for > "Breast tumor cell lines from pleural effusions"]. Journal of the National Cancer Institute 53 (3): 661 – 674. PMID 4412247. 
  119. Engel, LW; Young NA. (1978). [Expression error: Missing operand for > "Human breast carcinoma cells in continuous culture: a review"]. Cancer Research 38 (11 Pt 2): 4327 – 4339. PMID 212193. 
  120. Keydar, I; Chen L, Karby S, Weiss FR, Delarea J, Radu M, Chaitcik S, Brenner HJ. (1979). [Expression error: Missing operand for > "Establishment and characterization of a cell line of human breast carcinoma origin"]. European Journal of Cancer 15 (5): 659 – 670. PMID 228940. 

External links

Template:Wikibooks



Wikipedia-logo.png The basis of this article is contributed from Wikipedia.Org. These articles are licensed under the GNU Free Documentation License It may have since been edited beyond all recognition. But we thank Wikipedia for allowing its use.
Please discuss further on the talk page.

af:Borskanker ar:سرطان الثدي bn:স্তন ক্যান্সার bs:Tumori dojke bg:Рак на гърдата ca:Càncer de mama cs:Karcinom prsu da:Brystkræft de:Brustkrebs el:Καρκίνος του μαστού es:Cáncer de mama eo:Mama kancero fa:سرطان پستان fo:Bróstkrabbi fr:Cancer du sein ko:유방암 hr:Rak dojke id:Kanker payudara is:Brjóstakrabbamein it:Neoplasie della mammella he:סרטן השד ka:მკერდის კიბო la:Cancer mammae hu:Emlőrák mk:Рак на дојка arz:سرطان الثدى ms:Penyakit barah payudara nl:Borstkanker ja:乳癌 no:Brystkreft pl:Rak sutka pt:Câncer de mama ro:Cancer mamar ru:Рак молочной железы simple:Breast cancer sk:Karcinóm prsníka sr:Rak dojke fi:Rintasyöpä sv:Bröstcancer ta:மார்பக புற்றுநோய் th:มะเร็งเต้านม tr:Meme kanseri ur:سرطان پستان vi:Ung thư vú bat-smg:Krūtėis viežīs zh:乳癌

  • Currently 0.00/5

Rating: 0.0/5 (0 votes cast) login to rate

Add to Favorite Print This Page Publish on Twitter
Bookmark and Share
close about Number of comments per page:
Time format: relative absolute
You need JavaScript enabled for viewing comments




Languages: English • FrenchSpanishChineseOthers